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Background: Orofacial granulomatosis (OFG) causes chronic, disfiguring, granulomatous inflammation of the lips
and oral mucosa. A proportion of cases have co-existing intestinal Crohn’s disease (CD). The pathogenesis is
unknown but has recently been linked to dietary sensitivity. Although allergy has been suggested as an aetiological
factor in OFG there are few published data to support this link. In this study, we sought clinical evidence of allergy
in a series of patients with OFG and compared this to a series of patients with inflammatory bowel disease (IBD)
without oral involvement and to population control estimates.
Methods: Prevalence rates of allergy and oral allergy syndrome (OAS) were determined in 88 patients with OFG
using questionnaires, skin prick tests, total and specific serum IgE levels. Allergy was also determined in 117 patients
with IBD without evidence of oral involvement (79 with CD and 38 with ulcerative colitis (UC)).
Results: Prevalence rates of allergy in patients with OFG were significantly greater than general population
estimates (82% versus 22% respectively p = <0.0005). Rates of allergy were also greater in those with CD (39%) and,
interestingly, highest in those with OFG and concurrent CD (87%). Conversely, whist OAS was common in allergic
OFG patients (35%) rates of OAS were significantly less in patients with concomitant CD (10% vs 44% with and
without CD respectively p = 0.006). Amongst CD patients, allergy was associated with perianal disease (p = 0.042)
but not with ileal, ileocolonic or colonic disease location. Allergy in UC (18%) was comparable to population
estimates.
Conclusion: We provide compelling clinical evidence for the association of allergy with OFG whether occurring
alone or in association with CD. The presence of gut CD increases this association but, conversely, reduces the
expression of OAS in those with atopy. Interestingly, there is no evidence of increased allergy in UC.
Keywords: Allergy, Food allergens, Orofacial granulomatosis, OFG, Oral allergy syndrome, OAS, Crohn’s disease,
Ulcerative colitis, Inflammatory bowel disease, IBDIntroduction
Orofacial granulomatosis (OFG) is a chronic inflammatory
disorder presenting characteristically with lip swelling. It
can also affect other sites in the oral cavity such as the gin-
givae, buccal mucosa and the floor of the mouth [1]. Most
cases of OFG present as a separate clinical entity, but a
proportion present in association with systemic conditions
such as intestinal Crohn’s disease (CD), sarcoidosis or the
Melkersson-Rosenthal syndrome (MRS) [2-4]. Although* Correspondence: jeremy.sanderson@kcl.ac.uk
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reproduction in any medium, provided the orCD and OFG share a number of clinical and histological
features, the exact relationship between the two conditions
is unknown [5]. Non-specific oral lesions, particularly aph-
thous stomatitis, are common in CD, usually reflecting
periods of nutritional deficit or active disease [6,7]. Con-
versely, OFG-like changes, usually lip swelling or buccal
involvement, are uncommon in established gut CD [8].
Clinical allergy in the form of hay fever, atopic eczema
or asthma has been reported as being more prevalent, af-
fecting 12% to 60% of OFG patients compared to 15% of
the general population [9-11]. In an early study of 75 pa-
tients with OFG, the incidence of allergy was reported as
60% [12]. This compares with a recent worldwide surveyd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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was reported as 22% [13]. Many diseases affecting the
orofacial region have an allergic basis and the role of diet-
ary antigens in particular in the aetiopathogenesis of OFG
is compelling [14,15]. Cinnamon and benzoates have been
found to be positive on patch testing in patients with a
variety of oral mucosal diseases including OFG [16]. Spe-
cific dietary exclusion of cinnamon and benzoates in pa-
tients with OFG results in objective improvement in
disease activity [17]. How these substances contribute to
the development of OFG is as yet unclear.
Furthermore, evidence of a role for immunoglobulin
E (IgE) in OFG comes from the identification of a novel
subset of B cells in the oral mucosa in patients with
OFG (subepithelial dendritic B cells), a proportion of
which are class-switched to IgE. This may provide the link
between dietary allergens and the induction of local oral
inflammation [18].
OFG has clinical similarities with the Oral Allergy Syn-
drome (OAS), a well recognised condition with a clear im-
munological pathogenesis [19,20]. Pathologically, OAS is
distinct in that permanent granulomatous inflammation is
not a feature. OAS defines a complex of symptoms in-
duced by exposure of the oropharyngeal mucosa to food
allergens in patients who are allergic to tree pollens, in
particular to silver birch. The relevant foods contain simi-
lar determinants to aeroallergens to which the susceptible
individual has been previously sensitised. IgE-mediated
immediate hypersensitivity reactions are clearly defined
and some patients also experience delayed (>24 hrs) re-
sponses which correlate with T cell recognition [21]. These
delayed reactions which follow IgE-mediated responses
can last up to one week but are not associated with a
granulomatous lesion.
Avoidance of the dietary triggers in OAS is the main
treatment modality and largely alleviates symptoms. There
are therefore some similarities between OAS and OFG in
terms of symptoms, triggers and treatment regimens.
The contribution of allergy, if any, to the development
of inflammatory bowel disease (IBD) has long been a mat-
ter for debate. Over 40 years ago, a greater prevalence of
allergic disorders in patients with CD and ulcerative colitis
(UC) compared to matched controls was demonstrated
[22]. Other studies have confirmed raised levels of serum
IgE in patients with IBD [23,24]. Furthermore, there has
also been a long established link between lung disease and
IBD [25]. Recently, an increase in allergic symptoms, re-
spiratory symptoms, abnormal lung function and skin
prick test (SPT) positivity to common allergens in patients
with IBD was confirmed [26].
Other studies have been less positive regarding the asso-
ciation of atopy and IBD. Previous studies were unable to
show any difference in atopy, as assessed by SPTs to a panel
of common allergens, between patients with IBD andhealthy controls [27,28]. They did however show a highly
significant increase in the number of positive SPTs to food
allergens. This increased response to food allergens was
replicated using specific serum IgE tests in 100 patients
with IBD compared to 100 matched healthy controls [29].
The aim of this study was to determine the rate of al-
lergy in a large cohort of patients with OFG and compare
this to a group of patients with IBD with no evidence of
oral involvement and to reported population estimates of
allergy.Methods
Clinical profile
Eighty-eight consecutive patients with biopsy-proven OFG
(mean age 37.1 years [range 8-84]; 43 female) were
recruited from those attending a multi-disciplinary oral
medicine/ gastroenterology out-patient clinic at Guy’s &
St. Thomas’ NHS Foundation Trust Hospital (GSTFT,
London, UK) between August 2007 and July 2009. The
diagnosis of OFG was based on characteristic clinical and
histological findings. Co-existent intestinal CD was diag-
nosed by standard endoscopic, radiological and histo-
logical criteria. In addition, a group of 117 consecutive
patients with confirmed IBD but no oral involvement
(mean age 39 years [range17-77 years]; 66 female) were
recruited from those attending the IBD service at GSTFT
(79 CD, 38 UC). Allergy testing was undertaken as part
of routine clinical practice in the assessment of OFG
and part of an OFG research program approved by the
Local Research Ethics Committee (Approval No. 95/5/6;
Lewisham & North Southwark REC).Allergy assessment
All patients completed an allergy questionnaire as part of
their initial assessment. This included identifying asthma,
eczema and allergic rhinitis as well as reactions to com-
mon allergens. SPTs to a panel of common allergens
(grass, silver birch, plane, house dust mite, cat and
candida) and to cinnamon and benzoate were performed.
Allergen extracts from Stallergenes France were used. His-
tamine and saline were used as positive and negative con-
trols respectively. Wheal size was assessed at fifteen
minutes and a reaction of more than 3 mm was taken to
be positive. Blood was also taken for measurement of
total and specific serum IgE levels (ImmunoCAP) to 6
allergens (mixed grasses, silver birch, cat dander, house
dust mite, apple and hazel nut). Specific IgE levels equal
to or greater than 0.70 KU/L (Grade II) were considered
positive. Clinical evidence for allergy was based on a posi-
tive history of asthma, eczema, allergic rhinitis or acute
food allergy. Allergy rates were compared to population
estimates [13].
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Data were analysed in the GraphPad Prism statistical PC
program (GraphPad Software, San Diego, California) using
the χ [2] test. A level of p < 0.05 was considered statisti-
cally significant.Results
Clinical evidence for allergy
There was no significant difference in the demographics
of the different patient groups studied. A positive history
of allergy was observed in 81.8% (72 of 88) of patients
with OFG which is significantly greater than the 22%
[13] estimated for the general population (p < 0.0005). It
was also significantly greater than the prevalence of al-
lergy in patients with CD (31 of 79 patients [39%]) with-
out oral involvement (82% vs.40.2%; p < 0.0005). The
presence of OFG with concurrent CD was associated
with allergy in 20 of 23 (87%) of cases, slightly higher
than the rate of allergy in OFG alone and significantly
greater than in patients with CD without oral involve-
ment (87% vs 39%, p < 0.0005). Younger patients (disease
onset ≤30 years of age) with OFG alone (no intestinal
CD) had the highest rates of allergy (35 of 37 patients;
95%) than those presenting later in life (17 of 28 pa-
tients; 61%) (p = 0.0007), though the older patients still
had a significantly higher rate of allergy than the general
population. There was no difference in allergy rates
amongst patients with OFG and concurrent CD when
stratified according to age of disease onset.
Table 1 shows the prevalence of allergy in CD
according to anatomical disease location (Montreal clas-
sification [30]) and by treatments received. Interestingly,
perianal involvement, previously shown to be more fre-
quent in patients with OFG [31] was the only location
for which allergy was more frequent (p = 0.042). There
was no association between allergy and need for surgeryTable 1 Prevalence of allergy in Crohn’s disease










Ileal only 7 3 0.72
Colon only 12 6 0.84
Ileo-colonic 31 23 0.72
Rectal 2 5 0.18
Perianal 6 11 0.04
Immunosuppression 32 24 0.64
Biologic ever 15 8 0.71
Surgery ever 30 18 0.71
> 1 resection 10 9 0.65or treatment with immunosuppression or biologics (in-
direct markers of a more severe disease course).
Conversely, only 7 of 38 (18%) of patients with UC
gave a history, not significantly different to population
estimates (22%) but significantly lower than that seen in
patients with CD (18% vs 40.2% respectively, p = 0.024).
Rates of allergy did not vary in UC according to extent
of involvement in UC.
Rates of oral allergy syndrome
Patients with OFG frequently reported immediate hyper-
sensitivity reactions in their mouth to certain foods. The
most common foods were fruits, particularly those shar-
ing the common Bet v1 epitope responsible for OAS
[19,20]. These included apple, orange, tomato, kiwi fruit,
peach, melon and hazelnuts. 25 of the 72 allergic pa-
tients with OFG had evidence of OAS (35%). When the
patients were separated according to the presence or ab-
sence of CD, there was significantly more OAS amongst
allergic OFG patients without CD compared to those
with concomitant CD (23 of 52 [44%] vs 2 of 20 [10%];
p = 0.006). The prevalence of OAS in the different pa-
tient groups is outlined in Table 2. The rate of OAS in
patients with SPT or specific IgE positivity to silver birch
was 43% (21 of 49 patients). This is not significantly dif-
ferent from previous observations in the literature [32].
The rate of OAS in those OFG patients without CD
sensitised to silver birch was 49% compared to 20% in
those OFG patients with concomitant CD. The presence
of CD per se was therefore associated with a lower rate
of OAS in all groups.
Clinical measures of allergy
Table 3 shows markers of allergy (SPT and serum IgE
levels) in our study. As expected, mean total IgE levels
were significantly raised in atopic patients with OFG
whether or not they had concurrent CD (see Table 3).
Atopic patients with OFG and concurrent CD had
higher mean IgE levels than those with OFG alone,
though this was not statistically significant (360 KU/l vs
224 KU/l p = NS). The prevalence of at least one positive
SPT in allergic OFG patients (with or without CD) was
90% compared to 8% in those without allergicTable 2 Prevalence of OAS in allergic OFG patients and
silver birch sensitised patients according to presence or
absence of concomitant CD
Patient
group
OAS (%) in allergic
group
OAS (%) in silver birch
sensitised group
OFG alone 23/52 (44%) 19/39 (49%)
OFG + CD 2/20 (10%) 2/10 (20%)
Total 25/ 72 (35%) 21/49 (43%)
Table 3 IgE sensitisation and skin prick tests in different patient groups
Allergic Non-allergic Allergic Non-allergic Allergic Non-allergic
OFG OFG OFG + CD OFG + CD Crohn’s alone Crohn’s alone
n = 52 n = 13 n =20 n = 3 n = 32 n = 49
Positive SPT result (%)
Grass 75 0 75 0 69 8
Silver 75 0 50 0 59 2
Birch
Cat 44 0 60 0 59 6
Derm 54 0 65 0 72 12
Plane 52 0 35 0 47 0
Candida 33 0 60 0 44 2
Cinnamon 19 0 35 0 16 0
Benzoate 13 8 30 0 13 0
Positive ImmunoCAP result; >Grade II
Grass 67 8 65 0 0
Silver 32 0 29 0 0
Birch
Cat 34 0 35
Derm 34 0 53 0
Apple 6 0 18 0
Hazel 30 0 29 0
Mean total IgE in KU/L 224 38 360 12
≥1 SPT positive 90 8 90 0 91 20
≥1 RAST positive 76 0 82 0
≥ SPT +/- RAST positive 90 13 90 0
SPT (Skin Prick Test), Total and Specific Serum IgE.
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(silver birch) were the most prevalent in our patient
population, present in 75% of allergic OFG patients (with
or without CD). 19% and 35% of the allergic OFG patients
(with and without CD respectively) were SPT positive to
cinnamon. Likewise, 13% and 30% (allergic OFG patients
with and without CD respectively) were SPT positive to
benzoates. The prevalence of 1 or more positive SPT
was 91% in allergic CD patients with no oral involve-
ment. As expected, in the absence of reported allergy,
SPT positivity was low in all groups.
Positive specific serum IgE titres also correlated well
with reported allergy. The prevalence of a positive test
(equal to or greater than 0.70 KU/L) was 76% in allergic
patients with OFG alone and 82% in allergic patients with
OFG and CD. In keeping with SPT results, mixed grasses
were the most prevalent of the six allergens tested. The
prevalence of at least one positive SPT or at least one posi-
tive specific serum IgE was 90% in allergic OFG patients
(irrespective of presence of CD) and, naturally, very low
(13%) in in patients with non-allergic OFG and zero in pa-
tients with non-allergic OFG with CD.Discussion
The findings in this study confirm the remarkable associ-
ation of allergy with OFG regardless of the presence or ab-
sence of concurrent intestinal CD. Rates of atopy have
been studied in a variety of other chronic inflammatory
disorders (granulomatous or not) and have not been found
to be raised, including sarcoidosis [33]. Indeed, in certain
conditions, for example, rheumatoid arthritis and multiple
sclerosis, atopy rates are reported to be lower than the
population average [34,35]. This fits with the finding in pa-
tients with UC in this study where allergy rates were no
different to those reported in the general population.
The high atopy rates in OFG and CD therefore appear
quite unique. In OFG, where atopy is near universal, the
obvious question is whether allergy is involved in the
pathogenesis of this rare condition. A role for allergy
would be supported by the clinical presentation (pa-
tients frequently report swelling after specific dietary or
other environmental exposure), the response to exclu-
sion diets (e.g. cinnamon- and benzoate-free) and the
novel finding on oral mucosal immunohistochemistry of a
dendritic B cell infiltrate expressing IgE [26].
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marked but still clearly higher than population controls.
An interesting question is whether the presence of atopy
might in some way modify the phenotype of CD, particu-
larly by altering the Th1/Th2 polarisation in the immune
response in the gut. In this study, colonic involvement was
more frequent in atopic CD compared to an ileal disease
site, counter-intuitive to the fact that patients with UC, a
pure colonic disease, have no increased atopy. Perianal in-
volvement was also more frequent in atopic CD, an obser-
vation probably explained by the previous finding that
OFG is, itself, associated with perianal CD more fre-
quently than expected [31]. Immunologically, CD is con-
ventionally considered a Th1 disease. The only study to
have addressed the cell infiltrate in OFG supports a Th1
profile in this condition as well. Conversely, allergic disor-
ders display a Th2 polarisation. In other settings, there
is evidence that concurrent atopy, for example allergic
asthma, modifies a co-existing chronic inflammatory dis-
ease. Likewise, helminthic infection in the gut provokes a
Th2 polarised response which, intriguingly, may modify
the activity of CD through a shift away from Th1 polarisa-
tion, used to advantage for example, in the administration
of Trichuris suis as therapy for IBD [36].
An explanation for a link between allergy and CD may
come from the hygiene hypothesis in which individuals
raised in a sanitary environment are more prone to de-
velop certain diseases in later life. It is thought that indi-
viduals who are exposed to enteric pathogens from an
early age are more protected from developing CD in the
future. Exposure to pathogens induces a Th1 response in
early life which renders individuals less susceptible to de-
veloping Th2 disease later in life. Hence, another possibil-
ity linking OFG/CD and allergy is a shared increase in
susceptibility arising from similar environmental factors
early in life, including helminthic infections, antibiotic use,
breastfeeding, family size/sibship, urban upbringing, per-
sonal and domestic hygiene [37-40]. This may particularly
apply to the link between CD and allergy but the rates of
allergy in OFG are too high to be explained simply by
shared environmental influence.
In support of the hygiene hypothesis, two recent pro-
spective studies have reported a slightly increased risk of
IBD in children who receive antibiotics in their first year
of life [38,39]. Further support comes from a Spanish
case-control study of 270 IBD patients which concluded
that better childhood living conditions are associated
with an increased IBD risk [40]. Interestingly, a recent
American study of 83 IBD patients and 54 healthy con-
trols found an increased frequency of brushing, dental
floss and breath freshener use at onset of IBD [41].
The rates of OAS in patients with OFG without CD are
as expected from other cohort studies [32], but are much
lower when OFG patients have concomitant CD. Thepresence of CD seems to significantly affect the clinical ex-
pression of OAS. Only 10% of allergic OFG patients with
concomitant CD have OAS, compared to 44% of allergic
patients with OFG alone. Only 20% of silver birch sensitised
OFG patients with concomitant CD have OAS, compared
to 49% of silver birch sensitised patients with OFG alone.
Nevertheless, the overlap between OFG and OAS raises the
intriguing possibility of both immediate and delayed hyper-
sensitivity occurring sequentially in the same patients. This
could also be a factor in the pathology of OFG.
Another feature of our cohort is that the prevalence of
allergy in the CD patients is elevated even further by the
presence of OFG. Indeed, in patients with OFG without
CD and with a young age of disease onset, allergy is
present in almost all patients (95%, 35 of 37 patients in this
study). SPT positivity in non-atopic patients with OFG
was comparable to that noted by Droste et al [42]. The
prevalence of at least one positive SPT in allergic OFG pa-
tients (90%) was far greater than the 55.4% reported by
Droste et al [42] in their most allergic group of patients.
The high prevalence of at least one positive SPT or at least
one positive specific serum IgE in allergic OFG patients
(90%) compares with 63.1% in the most allergic group
reported by Droste et al [42]. The rates of positivity to in-
dividual allergens with the SPT and the specific IgE tests
were also consistently higher in our OFG groups. Further-
more there was a good correlation between the SPT re-
sults and the specific IgE results in individual patients,
providing an objective internal control for these results.
The total serum IgE in allergic OFG patients has also
been found to be elevated, significantly more so than in pa-
tients with symptoms of nasal allergy [42]. This is with or
without the presence of concomitant CD. Taken together
this shows that parameters of clinical allergy in OFG are
elevated above levels seen in a typical allergic disorder
causing nasal symptoms. Although these are observational
data, they could imply an involvement of allergy in the
pathogenesis of OFG or vice versa. The data also suggest
there may be an overlap between OFG and OAS and that
some patients with OFG may benefit from exclusion of
foods which are implicated in OAS, above any current
dietary therapies used in the treatment of OFG alone.
The high incidence of atopy in our cohort is not fully
understood and we have no definitive evidence of SPT
and food substances. Recently, a small study in which
OFG patients with positive SPTs excluded cross reactive
foods showed that 2/14 patients responded very well and
required no further treatment [43]. Based on these find-
ings, we do not recommend routine SPTs in OFG pa-
tients and dietary intervention cannot be recommended
routinely, although a small number of patients do seem
to have an excellent response.
We do acknowledge some small limitations in our study.
The recent literature on cinnamon and benzoates relates
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perform SPT as the logistics of performing patch testing
was not possible in our clinic. Delayed late phase reactions
were not sought. Oral exposure also appears to be relevant,
however, SPTs were chosen to be performed as we wished
to distinguish between atopic and non-atopic patients.
Future studies may be designed to address these areas.
In conclusion, we provide strong clinical evidence that
patients with OFG have a strong allergic phenotype.
Alongside the histological changes noted by our group,
this may play a significant role in bridging the observed
specific hypersensitivity to allergens and pathogenesis of
OFG. The value of dietary interventions in OFG has
already been demonstrated with the successful use of a
cinnamon- and benzoate-free diet [17]. Our results sug-
gest that the identification of other specific food triggers
may lead to more successful individualized dietary treat-
ments for this difficult condition. We also provide inter-
esting data on the increased prevalence of allergy in
patients with IBD without oral involvement. The signifi-
cance of this is unclear and may simply reflect genetic
linkages between IBD and allergy. Further studies with
larger cohorts of patients are necessary to gain further
insight and for validation of this association.
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